glp 1 agonists adverse effects of GLP-1 class drugs. Gastrointestinal issues are JDD Buzz Series | Cutaneous
Description
23431, federalregister.gov, docket 2026-08552)
Conclusion Tirzepatide is likely to counteract most of the pathogenetic factors contributing to CKD in T2D, potentially representing a step forward in incretin-based therapy towards nephroprotection
2023;46(Supplement 1):S140S157
Currently, nearly 100 million people globally are affected by DR, and as the prevalence of diabetes continues to rise, this number is expected to grow, posing a significant burden on public health (82)
